Moxifloxacin Outperforms Azithromycin in M genitalium Cure
A recent study found that moxifloxacin is more effective than azithromycin for treating Mycoplasma genitalium infections. The trial involved 358 patients and demonstrated higher microbiologic cure rates with moxifloxacin. Researchers suggest it could be a first-line treatment where resistance testing is not available.
- ▪A 10-day regimen of moxifloxacin yielded significantly higher cure rates than a 6-day regimen of azithromycin.
- ▪The study was conducted at a tertiary care hospital in Italy from January 2018 to June 2024.
- ▪Among symptomatic patients, the cure rate was 85.7% with moxifloxacin compared to 56.8% with azithromycin.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with Mycoplasma genitalium (MG) infection, a 10-day regimen of moxifloxacin 400 mg daily yielded significantly higher microbiologic cure rates than a 6-day regimen of azithromycin 500 mg daily, supporting its use as a potential first-line treatment where resistance testing is unavailable.METHODOLOGY:Researchers conducted a phase 4 trial at a tertiary care hospital in Italy from January 2018 to June 2024 to demonstrate the superiority of moxifloxacin over azithromycin for treating MG infection in the absence of resistance testing.Overall, 358 patients with MG infection (median age, 36 years; 96.6% men) detected using multiplex polymerase chain reaction were randomly assigned to receive either moxifloxacin 400 mg once daily for 10 days (n = 193) or azithromycin 500 mg…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
